Overview

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the effect of voglibose on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Inositol
Vildagliptin
Voglibose
Criteria
Inclusion Criteria:

- Diabetic patients with inadequately controlled on diet therapy and exercise therapy
(HbA1c in the range 6.5 to 10.0% inclusive by NGSP)

Exclusion Criteria:

- Fasting plasma glucose ≥ 270 mg/dL A history of Type 1 diabetes or secondary forms of
diabetes Treatment of anti-diabetic agents including GLP-1 analogues within 8 weeks or
insulin within 6 months prior to screening Other protocol-defined inclusion/exclusion
criteria may apply